MedTrace Logo

New Oral Anticoagulants (NOAC) in Stroke Patients

NCT03826927 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1023

Last updated 2023-08-08

No results posted yet for this study

Summary

Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascular disease in a "real-world" setting at a stroke centre.

Conditions

Interventions

OTHER

treatment with NOACs or VKAs

treatment with NOACs or VKAs initiated or continued for prevention of ischemic events

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Philippe Lyrer, Prof. Dr. MD · University Hospital, Basel, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-01
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03826927 on ClinicalTrials.gov